These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21716146)

  • 1. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
    Stinchcombe TE; Peterman AH; Lee CB; Moore DT; Beaumont JL; Bradford DS; Bakri K; Taylor M; Crane JM; Schwartz G; Hensing TA; McElroy E; Niell HB; Harper HD; Pal S; Socinski MA
    J Thorac Oncol; 2011 Sep; 6(9):1569-77. PubMed ID: 21716146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
    Stinchcombe TE; Roder J; Peterman AH; Grigorieva J; Lee CB; Moore DT; Socinski MA
    J Thorac Oncol; 2013 Apr; 8(4):443-51. PubMed ID: 23370367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
    Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
    Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F
    Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
    Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
    J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
    Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
    Gridelli C; Ciardiello F; Gallo C; Feld R; Butts C; Gebbia V; Maione P; Morgillo F; Genestreti G; Favaretto A; Leighl N; Wierzbicki R; Cinieri S; Alam Y; Siena S; Tortora G; Felletti R; Riccardi F; Mancuso G; Rossi A; Cantile F; Tsao MS; Saieg M; da Cunha Santos G; Piccirillo MC; Di Maio M; Morabito A; Perrone F
    J Clin Oncol; 2012 Aug; 30(24):3002-11. PubMed ID: 22778317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
    Michael M; Pavlakis N; Clingan P; De Boer R; Johnston M; Clarke S
    Oncol Rep; 2012 Sep; 28(3):763-7. PubMed ID: 22710607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
    J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients.
    Grigorescu AC; Bala C
    J BUON; 2013; 18(1):188-94. PubMed ID: 23613405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).
    LeCaer H; Greillier L; Corre R; Jullian H; Crequit J; Falchero L; Dujon C; Berard H; Vergnenegre A; Chouaid C;
    Lung Cancer; 2012 Jul; 77(1):97-103. PubMed ID: 22405570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
    Satouchi M; Kotani Y; Katakami N; Shimada T; Urata Y; Yoshimura S; Funada Y; Hata A; Ando M; Negoro S
    J Thorac Oncol; 2010 May; 5(5):696-701. PubMed ID: 20147856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2
    Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL
    J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
    Mori K; Kobayashi H; Kamiyama Y; Kano Y; Kodama T
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):73-8. PubMed ID: 18941748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
    Iranzo V; Sirera R; Carrato A; Cabrera A; Jantus E; Guijarro R; Sanmartín E; Blasco A; Gil M; Gómez-Aldaraví L; González-Larriba JL; Massuti B; Velasco A; Provencio M; Rossell R; Camps C
    Clin Transl Oncol; 2011 Jun; 13(6):411-8. PubMed ID: 21680302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.